Combination GnRH antagonists for endometriosis: Balancing efficacy with side effects
Other
OA: gold
CC0
⤵ 5 in-corpus citations
AI-generated summary
This paper reviews trials of Relugolix, a combined hormone replacement therapy and GnRH antagonist, for treating endometriosis-associated pain.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Endometriosis is a chronic pain condition affecting 1 in 10 women. There is an unmet need for better medical treatments for endometriosis. We spotlight trials of a single preparation combined HRT-GnRH antagonist (Relugolix) by Giudice et al.,1 for endometriosis-associated pain.
My notes (saved in your browser only)
Outcome instruments
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (10)
- O-132 Sustained efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT 52-week data via openalex
- Once daily oral relugolix combination therapy versus placebo in patients with endometriosis-associated pain: two replicate phase 3, randomised, double-blind, studies (SPIRIT 1 and 2) via openalex
- SnapShot: Endometriosis via openalex
- Top ten endometriosis research priorities in the UK and Ireland via openalex
- Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist via openalex
- Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study via openalex
- W4214754424 via openalex
- W3165294846 via openalex
- W3013010875 via openalex
- W2132577372 via openalex
Cited by (5)
- Investigational drugs for the treatment of dysmenorrhea 2024
- Is high-intensity focused ultrasound a magical solution to endometriosis? A systematic review 2024
- Efficacy and Safety of Oral Gonadotropin-Releasing Hormone Antagonist, Relugolix, in Endometriosis: A Meta-Analysis of Randomized Clinical Trials 2024
- Transforming Endometriosis Management: Insights from a Six-Year Application of the 4P Approach 2024
- Update on the management of endometriosis-associated pain in France 2023
Source provenance
- europepmc
- last seen: 2026-10-18T09:30:06.152893+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-08T21:36:45.364535+00:00
License: CC0
· commercial use OK